Richard Hartman
Psychiatry · Norman, OKNPI 1639110752
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 438 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $34.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Alkermes, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $4K from 18 others
What the payments were for
- Food & beverage$14,88399%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 68 | $2,558 |
| Alkermes, Inc. | 60 | $2,269 |
| AbbVie(2 entities) | 84 | $1,832 |
| Johnson & Johnson | 20 | $1,484 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,452 |
| Otsuka America Pharmaceutical, Inc. | 27 | $1,233 |
| Acadia Pharmaceuticals Inc | 34 | $1,027 |
| E.r. Squibb & Sons, L.L.C. | 10 | $641 |
| Vanda Pharmaceuticals Inc. | 12 | $580 |
| Indivior Inc. | 28 | $491 |
| Neurocrine Biosciences, Inc. | 5 | $310 |
| Lundbeck LLC | 13 | $288 |
| Sunovion Pharmaceuticals Inc. | 4 | $175 |
| Pear Therapeutics (US), Inc. | 2 | $146 |
| Corium, LLC | 1 | $125 |
| Novo Nordisk | 1 | $116 |
| Noven Pharmaceuticals, Inc. | 1 | $108 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $36 |
| Gilead | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Bioxcel Therapeutics, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$2,368
- LYBALVI$2,272
- INVEGA SUSTENNA$760
- VRAYLAR$678
- COBENFY$595
- ARISTADA INITIO$592
- Austedo XR$592
- NUPLAZID$582
- CAPLYTA$576
- AUSTEDO$550
- SPRAVATO$459
- UZEDY$349
- Fanapt$341
- REXULTI$242
- INVEGA TRINZA$241
- RESET-O$135
- Azstarys$125
- ABILIFY MAINTENA$120
- ABILIFY ASIMTUFII$120
- RYBELSUS$116
How this compares
$14,986 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 22 | $16,319 |
| Clozapine | 48 | $2,368 |
| Divalproex Sodium | 51 | $1,746 |
| Sertraline Hcl | 84 | $1,328 |
| Aripiprazole | 31 | $1,155 |
| Olanzapine | 31 | $707 |
| Donepezil Hcl | 23 | $644 |
| Trazodone Hcl | 44 | $592 |
| Citalopram HbrCitalopram Hydrobromide | 28 | $451 |
| Quetiapine Fumarate | 21 | $392 |
| Doxepin Hcl | 13 | $386 |
| Levetiracetam | 12 | $349 |
| Buspirone Hcl | 26 | $330 |
| Mirtazapine | 15 | $189 |
| Escitalopram Oxalate | 13 | $185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,233 | $16,31922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Norman
- Julia IrwinNorman$16K
- Vivian HasbrookNorman$12K
- Uzma ZaidiNorman$11K
- Jack GrayNorman$9K
- Joseph RippergerNorman$6K
- Keenan SmartNorman$6K
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.